Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spark Therapeutics, Inc.

https://sparktx.com/

Latest From Spark Therapeutics, Inc.

For Cell And Gene Therapies, Expedited Designation And Complex Questions Improve FDA Meeting Chances

Designation as a regenerative medicine advanced therapy or breakthrough therapy ‘dramatically increases’ the likelihood of getting a meeting with the agency, Office of Tissues and Advanced Therapies’ Wilson Bryan says; more complex and innovative products, and more challenging questions, also are likely to win sponsors an audience with the FDA.

Gene Therapy Regenerative Medicine

US FDA’s Cell/Gene Therapy Office Looks To Improve Clarity Of Advice Through Written Responses

Standardizing the process for providing clarifications following sponsor meetings, particularly with regard to the written response-only format, is one of several solutions being piloted by the Office of Tissues and Advanced Therapies as part of its ‘growth program,’ which aims to expedite advances in cell/gene therapies while also improving staff satisfaction.

Gene Therapy Regenerative Medicine

Gene Therapy Reviews Return To US FDA Advisory Committee Schedule

The upcoming review of two novel gene therapies from bluebird bio marks will be the first time the US FDA’s CTGTAC has met for a genetic product review in five years. That is a surprisingly long gap – and one that probably will not be repeated.

Gene Therapy Advisory Committees

CAR-T Manufacturing: Guidance Anticipates Platform Challenges And Opportunities

Draft from US FDA advises sponsors on how to draw from platform knowledge, while anticipating issues associated with emerging centralized and distributed manufacturing approaches for autologous and allogeneic products and their viral vectors.

Manufacturing Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Genable Technologies Limited
    • Roche Holding AG (RHHBY)
UsernamePublicRestriction

Register